DT-FECD

DT-FECD is a preclinical-stage small molecule therapeutic candidate developed by Design Therapeutics for the treatment of Fuchs Endothelial Corneal Dystrophy (FECD). Utilizing the company's proprietary GeneTAC (Gene Targeted Axial Chimera) platform, DT-FECD is designed to specifically target and bind to the CTG repeat expansions in the TCF4 gene, which are the primary genetic cause of FECD in the majority of patients. The mechanism involves modulating the expression of the affected gene or preventing the toxic RNA/protein gain-of-function associated with the repeats, aiming to halt or reverse the progression of corneal endothelial cell loss characteristic of the disease. As a GeneTAC molecule, it functions as a chimera that recruits cellular machinery to the specific genetic site of the repeat expansion.